CRISPR Therapeutics: An Uninspiring Start For Casgevy
CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...
Nasdaq18d
Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates
The company is developing its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for the treatment of adult patients with sickle cell disease (SCD). In December ...
Nasdaq19d
Fulcrum Therapeutics Reports Q4 and Full Year 2024 Financial Results and Updates on Pioneering SCD Trial
The company is progressing in its Phase 1b PIONEER trial for pociredir, a potential treatment for sickle cell disease (SCD), having enrolled ten patients in the 12 mg dose cohort and expecting to ...
Seeking Alpha19d
Fulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call Transcript
The latter part of 2024 and early 2025 has been an exciting period for Fulcrum with notable progress for our lead program, pociredir, currently in development for the treatment of sickle cell disease.
Associated Press26d
Takeaways from AP’s investigation into dozens of deaths of police recruits
Copyright 2025 The Associated Press. All Rights Reserved. At least 29 recruits have died during basic training at law enforcement academies nationwide in the last ...